JP Morgan Upgrades C4 Therapeutics to Neutral, Announces $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph has upgraded C4 Therapeutics (NASDAQ:CCCC) from Underweight to Neutral and set a price target of $6.

January 29, 2024 | 10:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
C4 Therapeutics was upgraded by JP Morgan from Underweight to Neutral with a new price target of $6.
Upgrades by major analysts like JP Morgan can lead to increased investor confidence and potential short-term price increases as the market adjusts to the new rating. The setting of a price target provides a benchmark that investors may use to gauge the stock's potential, influencing trading behavior.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100